# US 7,611,718 B1 · Attenuation of cytomegalovirus virulence

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,718 B1
- Document ID: US7611718B1
- Status: Granted
- Kind: B1
- Application number: 11/614,035
- Filed: 2006-12-20
- Granted: 2009-11-03
- Earliest claimed: 2000-11-28
- Assignees: MedImmune, LLC
- Inventors: George Kemble; Gregory M. Duke; Richard Spaete
- Web page: https://patentgrep.com/patent/US7611718B1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 31/12: Antivirals
- A61P 37/04: Immunostimulants
- C12N 2710/16162: by genetic engineering
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.

## Claims

### Claim 1

A chimeric cytomegalovirus (CMV) virus which comprises: (a) the polynucleotide sequence of a high-passage Towne genome from nucleotides 1 to 99000; (b) the polynucleotide sequence of a Toledo genome from nucleotides 108094 to 203136; (c) the polynucleotide sequence of a high passage Towne genome from nucleotides 205803 to S-term, wherein the high-passage Towne genome has been passaged at least 50 times and wherein the nucleotide number of the Towne and Toledo genomes is according to the numbering convention of the AD169 genome.

### Claim 2

A chimeric CMV virus which comprises: (a) the polynucleotide sequence of a high-passage Towne genome from nucleotides 1 to 99000; (b) a crossover region comprising SEQ ID NO.: 29; (c) the polynucleotide sequence of a Toledo genome from nucleotides 108094 to 203136; (d) a crossover region comprising SEQ ID NO.: 26; (e) the polynucleotide sequence of a high passage Towne genome from nucleotides 205803 to S-term, wherein the high-passage Towne genome has been passaged at least 50 times and wherein the nucleotide number of the Towne and Toledo genomes is according to the numbering convention of the AD169 genome.

### Claim 3 (depends on 1)

An immunogenic composition comprising the chimeric virus of claim 1.

### Claim 4 (depends on 1)

An immunogenic composition comprising the chimeric virus of claim 1.

### Claim 5 (depends on 3)

A method of inducing an immune response comprising administering to a human an immunological composition of claim 3 in an amount sufficient to stimulate an immune response in said human.

### Claim 6 (depends on 4)

A method of inducing an immune response comprising administering to a human an immunological composition of claim 4 in an amount sufficient to stimulate an immune response in said human.